Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, randomized phase II study of S-1 plus resminostat versus S-1 plus placebo in patients with platinum-gemcitabine combination refractory biliary tract cancer (BTC).

Next Previous
X
Search
Trial Profile

A double-blind, randomized phase II study of S-1 plus resminostat versus S-1 plus placebo in patients with platinum-gemcitabine combination refractory biliary tract cancer (BTC).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Sponsors Yakult Honsha

    • Most Recent Events

    • 19 Apr 2018 Final results are expected to be available by mid-2020, according to a 4SC media release.
    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 21 Mar 2018 According to a 4SC media release, this trial is expected to initiate in in H1 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top